Zions Bancorporation National Association UT Invests $27,000 in DexCom, Inc. (NASDAQ:DXCM)

Zions Bancorporation National Association UT acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 391 shares of the medical device company’s stock, valued at approximately $27,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Forsta AP Fonden grew its stake in DexCom by 6.0% in the first quarter. Forsta AP Fonden now owns 88,100 shares of the medical device company’s stock worth $6,016,000 after purchasing an additional 5,000 shares in the last quarter. National Bank of Canada FI grew its stake in DexCom by 139.6% in the first quarter. National Bank of Canada FI now owns 569,011 shares of the medical device company’s stock worth $38,858,000 after purchasing an additional 331,528 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in DexCom by 8.7% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 988,778 shares of the medical device company’s stock worth $67,524,000 after purchasing an additional 79,194 shares in the last quarter. Headlands Technologies LLC grew its stake in DexCom by 293.5% in the first quarter. Headlands Technologies LLC now owns 24,587 shares of the medical device company’s stock worth $1,679,000 after purchasing an additional 18,339 shares in the last quarter. Finally, Monetta Financial Services Inc. bought a new position in DexCom in the first quarter worth approximately $683,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Robert W. Baird dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Mizuho increased their price objective on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Oppenheimer increased their target price on DexCom from $95.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, July 31st. UBS Group increased their target price on DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.89.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 6,184 shares of the firm’s stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president owned 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director owned 56,621 shares of the company’s stock, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,656 shares of company stock worth $2,412,191. Insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $79.96 on Thursday. The firm has a market capitalization of $31.36 billion, a price-to-earnings ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business has a fifty day moving average of $83.28 and a 200 day moving average of $80.19. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the business posted $0.43 EPS. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.